FAK Inhibition Decreases Hepatoblastoma Survival Both In Vitro and In Vivo.

@article{Gillory2013FAKID,
  title={FAK Inhibition Decreases Hepatoblastoma Survival Both In Vitro and In Vivo.},
  author={Lauren A. Gillory and Jerry E. Stewart and Michael L. Megison and Hugh C. Nabers and Elizabeth C Mroczek-Musulman and Elizabeth Ann Beierle},
  journal={Translational oncology},
  year={2013},
  volume={6 2},
  pages={206-15}
}
Hepatoblastoma is the most frequently diagnosed liver tumor of childhood, and children with advanced, metastatic or relapsed disease have a disease-free survival rate under 50%. Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase that is important in many facets of tumor development and progression. FAK has been found in other pediatric solid tumors and in adult hepatocellular carcinoma, leading us to hypothesize that FAK would be present in hepatoblastoma and would impact its cellular… CONTINUE READING